---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-278804"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:11:44.119196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aldeyra expands RASP platform to CNS diseases; reproxalap manufacturing inspections closed

## Summary
- ADX-248 preclinical results in Parkinson's & ALS models showed improved grip strength, balance, and CNS biomarkers.
- FDA completed reproxalap drug substance and product facility inspections; closed with VAI designation, no further action.
- Aldeyra expanded RASP platform to central nervous system diseases; ADX-248 is oral next-gen RASP modulator.
- Reproxalap is a first-in-class investigational candidate for dry eye disease signs and symptoms.

## SEC filing metadata
- accession: 0001193125-25-278804
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312525278804/0001193125-25-278804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312525278804/aldx-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-278804
- JSON: https://secwatch.observer/filing/0001193125-25-278804.json
- Plain text: https://secwatch.observer/filing/0001193125-25-278804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.